Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
